Braftovi™ (encorafenib) and Mektovi® (binimetinib) – New drug approval
June 27, 2018 - Array BioPharma announced the FDA approval of Braftovi (encorafenib) and Mektovi (binimetinib), in combination for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Top